A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
A Phase 2b/3, Double-masked, Randomized, Vehicle-controlled, Multicenter Study Evaluating Licaminlimab in Dry Eye Disease Patients With a Specific TNFR1 Genotype
Oculis
160 participants
Apr 16, 2026
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Artificial tear eye drop run-in three times daily (TID) for approximately 14 days.
Licaminlimab eye drops three times daily (TID) for 29 days.
Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days.
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07548632